Keyphrases
Type 2 Diabetic Patients
100%
Albuminuria
100%
Spironolactone
100%
Hypertension
100%
Urine Proteome
100%
Albumin-to-creatinine Ratio
71%
Plasma Proteomics
42%
Type 2 Diabetes Mellitus (T2DM)
28%
Placebo
28%
Inter-patient Variability
28%
Treatment Assignment
14%
Renin-angiotensin System Inhibitors
14%
95th Percentile
14%
Double-blind Randomized Clinical Trial
14%
Clinical Trials
14%
Treatment Response
14%
Large Reduction
14%
CE-MS
14%
Kidney Disease Progression
14%
Confidence Interval
14%
Patients with Diabetes
14%
Placebo Groups
14%
Mineralocorticoid Receptor Antagonists
14%
Biochemistry, Genetics and Molecular Biology
Proteomics
100%
Spironolactone
100%
Creatinine
71%
Receptor Antagonist
14%
Mass Spectrometry
14%
Mineralocorticoid Receptor
14%
Randomized Clinical Trial
14%
Capillary Electrophoresis
14%
Clinical Trial
14%
Renin Angiotensin Aldosterone System
14%